Sublingual Immunotherapy
Publication Date: March 1, 2017
Key Points
Key Points
- It is crucial that the practicing allergist separate the data on FDA reviewed products that have led to approval of these products (ie, dust mites, grass and ragweed tablets) from the data in the literature with other allergens and other formulations (eg, liquid formulations) that have not undergone the rigor of FDA review.
Diagnosis
...gnosis...
...rld Allergy Organization Grading Syste...
...2. Description of Local Adverse Effects...
Treatment
...atment
...roved SLIT products for the treatme...
...an should be aware that SLIT may not be suitab...
...roved SLIT products very cautiously in the pregnan...
...o not assume dosing equivalence betwe...
...r the patient’s first dose of SLIT in a medical...
...cribe epinephrine (either an autoinjector...
...a patient’s SLIT dose if they hav...
Schedule patients receiving SLIT ther...
...pproved products for SLIT in the United S...
...uggested Guidelines for the Practicing All...
...le 4. FDA-Approved Sublingual TabletsHaving...